Literature DB >> 21434959

Utility of measuring plasma N-terminal pro-brain natriuretic peptide in detecting hypertrophic cardiomyopathy and differentiating grades of severity in cats.

Gerhard Wess1, Patricia Daisenberger, Monia Mahling, Johannes Hirschberger, Katrin Hartmann.   

Abstract

BACKGROUND: Cats with hypertrophic cardiomyopathy (HCM) often have no clinical signs or subtle signs. Measurement of N-terminal pro-brain natriuretic peptide (NT-proBNP) has been demonstrated in people to be highly specific for heart disease and also correlates with severity of HCM. NT-proBNP may also be valuable in detecting and grading HCM in cats, but results to date have been equivocal.
OBJECTIVES: The aims of this study were to evaluate NT-proBNP as a screening test for diagnosis of HCM in cats and determine an appropriate cut-off value and to determine if NT-proBNP concentrations correlated with severity of HCM in cats.
METHODS: Plasma NT-proBNP concentrations were measured in 201 cats using an ELISA designed for use in cats. Cats were classified using echocardiography as clinically healthy controls (n=99) or cats with equivocal (n=9), mild (n=15), moderate (n=17), or severe (n=61) HCM.
RESULTS: NT-proBNP concentrations (median; 25th-75th interquartile percentiles) in mildly (216.1; 87.6-392.5 pmol/L), moderately (282.7; 131.9-466.6 pmol/L), and severely (839.5; 655.3-1046.4 pmol/L) affected cats were significantly higher than those in healthy controls (18.9; 3.4-62.4 pmol/L). Concentrations in severely affected cats were significantly higher than in cats from other HCM groups. There was no significant difference between mild and moderate HCM. Cut-off values >49 pmol/L had a sensitivity of 97.8% and specificity of 66.7%; >100 pmol/L had a sensitivity of 92.4% and specificity of 93.9%; and >150 pmol/L had a sensitivity of 88% and a specificity of 100%.
CONCLUSIONS: NT-proBNP with a cut-off value of >100 pmol/L was useful in detecting even mild HCM. Cats with increased NT-proBNP concentrations should be examined by echocardiography. ©2011 American Society for Veterinary Clinical Pathology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21434959     DOI: 10.1111/j.1939-165X.2011.00305.x

Source DB:  PubMed          Journal:  Vet Clin Pathol        ISSN: 0275-6382            Impact factor:   1.180


  17 in total

1.  End-stage hypertrophic cardiomyopathy in a cat.

Authors:  Andrew J M White
Journal:  Can Vet J       Date:  2015-05       Impact factor: 1.008

2.  Plasma cardiac troponin I concentration and cardiac death in cats with hypertrophic cardiomyopathy.

Authors:  K Borgeat; K Sherwood; J R Payne; V Luis Fuentes; D J Connolly
Journal:  J Vet Intern Med       Date:  2014-10-15       Impact factor: 3.333

3.  Cardiac biomarkers in hyperthyroid cats.

Authors:  J K Sangster; D L Panciera; J A Abbott; K C Zimmerman; A C Lantis
Journal:  J Vet Intern Med       Date:  2013-12-18       Impact factor: 3.333

4.  Investigation of an N-Terminal Prohormone of Brain Natriuretic Peptide Point-of-Care ELISA in Clinically Normal Cats and Cats With Cardiac Disease.

Authors:  A N Harris; S S Beatty; A H Estrada; B Winter; M Bohannon; I Sosa; J Hanscom; C A Mainville; A E Gallagher
Journal:  J Vet Intern Med       Date:  2017-06-15       Impact factor: 3.333

5.  Assessment of a bedside test for N-terminal pro B-type natriuretic peptide (NT-proBNP) to differentiate cardiac from non-cardiac causes of pleural effusion in cats.

Authors:  Gabriel Wurtinger; Estelle Henrich; Nicolai Hildebrandt; Nicola Wiedemann; Matthias Schneider; Esther Hassdenteufel
Journal:  BMC Vet Res       Date:  2017-12-20       Impact factor: 2.741

6.  Accuracy of methods for diagnosing heart diseases in cats.

Authors:  Tanarut Laudhittirut; Natrada Rujivipat; Kornnicha Saringkarisate; Peeraya Soponpattana; Teerawat Tunwichai; Sirilak Disatian Surachetpong
Journal:  Vet World       Date:  2020-05-09

7.  Evaluation of a sensitive cardiac troponin I assay as a screening test for the diagnosis of hypertrophic cardiomyopathy in cats.

Authors:  S Hertzsch; A Roos; G Wess
Journal:  J Vet Intern Med       Date:  2019-04-16       Impact factor: 3.333

8.  The use of focused cardiac ultrasound to screen for occult heart disease in asymptomatic cats.

Authors:  Kerry A Loughran; John E Rush; Elizabeth A Rozanski; Mark A Oyama; Éva Larouche-Lebel; Marc S Kraus
Journal:  J Vet Intern Med       Date:  2019-07-17       Impact factor: 3.333

9.  Effect of feline characteristics on plasma N-terminal-prohormone B-type natriuretic peptide concentration and comparison of a point-of-care test and an ELISA test.

Authors:  Sofia Hanås; Bodil S Holst; Katja Höglund; Jens Häggström; Anna Tidholm; Ingrid Ljungvall
Journal:  J Vet Intern Med       Date:  2020-03-22       Impact factor: 3.333

10.  ACVIM consensus statement guidelines for the classification, diagnosis, and management of cardiomyopathies in cats.

Authors:  Virginia Luis Fuentes; Jonathan Abbott; Valérie Chetboul; Etienne Côté; Philip R Fox; Jens Häggström; Mark D Kittleson; Karsten Schober; Joshua A Stern
Journal:  J Vet Intern Med       Date:  2020-04-03       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.